Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 8 for:    brincidofovir adenovirus

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02596997
Expanded Access Status : Available
First Posted : November 4, 2015
Last Update Posted : May 24, 2018
Sponsor:
Information provided by (Responsible Party):
Chimerix

Tracking Information
First Submitted Date November 3, 2015
First Posted Date November 4, 2015
Last Update Posted Date May 24, 2018
 
Descriptive Information
Brief Title Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Brief Summary Provide patients with serious AdV infection or disease access to treatment with BCV.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Drug: Brincidofovir
Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
Other Name: BCV CMX001
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Contacts
Contact: Garrett Nichols, MD 919-287-6006 gnichols@chimerix.com
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02596997
Responsible Party Chimerix
Study Sponsor Chimerix
Collaborators Not Provided
Investigators Not Provided
PRS Account Chimerix
Verification Date May 2018